BiotechTube

Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Macular Degenerative Disease

Conditions

Macular Degenerative Disease

Trial Timeline

Jan 8, 2018 → Mar 31, 2029

NCT ID
NCT03167203

About Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells is a phase 1/2 stage product being developed by Astellas Pharma for Macular Degenerative Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03167203. Target conditions include Macular Degenerative Disease.

What happened to similar drugs?

20 of 20 similar drugs in Macular Degenerative Disease were approved

Approved (20) Terminated (3) Active (0)
✅FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
✅FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
✅Aflibercept Injection [Eylea]Santen PharmaceuticalApproved
✅Ozurdex + AfliberceptAbbVieApproved
✅RanibizumabNovartisApproved
✅ranibizumabNovartisApproved
✅intravitreal injection of Brolucizumab 6 mg in study eyeNovartisApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03167203Phase 1/2Recruiting

Competing Products

20 competing products in Macular Degenerative Disease

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
25
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
4 mg CLS-TA + Sham + IVT afliberceptClearside BiomedicalPhase 2
25
suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or AvastinClearside BiomedicalPhase 3
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
KVD001 InjectionKalVista PharmaceuticalsPhase 2
29
KVD001 InjectionKalVista PharmaceuticalsPhase 1
23
FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
33
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
33
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 2
25
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 1
19
CT-P42 + EyleaCelltrionPhase 3
40
Faricimab + AfliberceptChugai PharmaceuticalPhase 3
40
Faricimab + AfliberceptChugai PharmaceuticalPhase 3
40
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Fovista® + bevacizumab + ranibizumab + afliberceptAstellas PharmaPhase 2
27
MA09-hRPEAstellas PharmaPre-clinical
26